The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Potential therapeutic targets in subsets of PTCL
In this video, Francisco Vega, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into potential therapeutic targets in various subsets of peripheral T-cell lymphoma (PTCL), including inhibitors of DNMT3A and IDH2, and the potential role of venetoclax and combination strategies in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
